Treatment of leukemia L1210 and P388 by arabinosylcytosine-polysaccharide conjugates.
Conjugates of 1-beta-D-arabinofuranosylcytosine (araC) with two polysaccharides such as polygalacturonic acid (PGA) and carboxymethylated yeast beta-D-glucan (CMG) were tested for their antileukemic activity in vitro on a L1210 cell line in suspension culture, in soft agar assay and in vivo on L1210, L1210/araC- and P388-leukemia-bearing mice. Both conjugates showed high activity in vitro in soft agar assay, compared with araC. Single administration of PGA-araC or CMG-araC increased the survival time 1.5 x or 1.7 x, respectively, compared with araC in vivo in L1210-leukemia-bearing mice. The conjugates were not active against araC-resistant leukemia line L1210/araC. The marked effect of both PGA-araC and CMG-araC against leukemia L1210 and P388 is probably due to the prolonged release of free araC from conjugates caused by hydrolysis.
Novotný
L
L
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Czechoslovakia.
Balázová
E
E
Sandula
J
J
Ujházy
V
V
Kéry
V
V
D000818:Animals; D003561:Cytarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis; D005260:Female; D005936:Glucans / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000378:metabolism; D007941:Leukemia P388 / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D010368:Pectins / Q000627:therapeutic use*; D047071:beta-Glucans
D005936:Glucans; D047071:beta-Glucans; C066878:carboxymethyl-beta-glucan-cytarabine; C066879:polygalacturonic acid-cytarabine; D003561:Cytarabine; D010368:Pectins; D004247:DNA